Zobrazeno 1 - 10
of 335
pro vyhledávání: '"Scott N Gettinger"'
Autor:
Scott N. Gettinger, MD, Rudolf M. Huber, MD, PhD, Dong-Wan Kim, MD, PhD, Lyudmila Bazhenova, MD, Karin Holmskov Hansen, MD, Marcello Tiseo, MD, Corey J. Langer, MD, FACP, Luis G. Paz-Ares Rodríguez, MD, PhD, Howard L. West, MD, Karen L. Reckamp, MD, MS, Glen J. Weiss, MD, Egbert F. Smit, MD, PhD, Maximilian J. Hochmair, MD, Sang-We Kim, MD, PhD, Myung-Ju Ahn, MD, PhD, Edward S. Kim, MD, FACP, Harry J.M. Groen, MD, PhD, Joanna Pye, MS, Yuyin Liu, PhD, Pingkuan Zhang, MD, Florin Vranceanu, MD, PhD, D. Ross Camidge, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100385- (2022)
Introduction: We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK–rearrangement positive (ALK+) NSCLC. Methods: The phase 1/2 study evaluated brigatinib 30 to 300 mg/d in patients with advanced maligna
Externí odkaz:
https://doaj.org/article/78d40f5a880944a8b24323de142222e5
Autor:
Dong-Wan Kim, MD, PhD, Shirish Gadgeel, MD, Scott N. Gettinger, MD, Gregory J. Riely, MD, PhD, Geoffrey R. Oxnard, MD, Tarek Mekhail, MD, Peter Schmid, MD, PhD, Afshin Dowlati, MD, Rebecca S. Heist, MD, MPH, Antoinette J. Wozniak, MD, Jatinder Singh, PhD, Edward Cha, MD, PhD, Jessica Spahn, PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100367- (2022)
Introduction: Alectinib is a preferred first-line treatment option for advanced ALK-positive NSCLC. Combination regimens of alectinib with immune checkpoint inhibitors are being evaluated for synergistic effects. Methods: Adults with treatment-naive,
Externí odkaz:
https://doaj.org/article/ef3f254cb8784bd19307c98d578cc81c
Autor:
Daniel Carvajal-Hausdorf, Mehmet Altan, Vamsidhar Velcheti, Scott N. Gettinger, Roy S. Herbst, David L. Rimm, Kurt A. Schalper
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Abstract Background Small cell lung cancer (SCLC) accounts for 10–15% of all lung malignancies and its prognosis is dismal. Although early studies have shown promising clinical activity of immune checkpoint blockers, the immune composition and expr
Externí odkaz:
https://doaj.org/article/95ad26b6988545f3b24fc5c049322f04
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-13 (2018)
Abstract Background Immunotherapy is at the forefront of modern oncologic care. Various novel therapies have targeted all three layers of tumor biology: tumor, niche, and immune system with a range of promising results. One emerging class in both pri
Externí odkaz:
https://doaj.org/article/beb5bcf9f277480294b0437be21c9d79
Autor:
Lucas C. Adam, Junaid Raja, Johannes M. Ludwig, Adebowale Adeniran, Scott N. Gettinger, Hyun S. Kim
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Abstract Novel approaches with checkpoint inhibitors in immunotherapy continue to be essential in the treatment of non-small cell lung cancer (NSCLC). However, the low rate of primary response and the development of acquired resistance during the imm
Externí odkaz:
https://doaj.org/article/f4d48f789b46413493544b8aa0424e12
Autor:
Joseph M Unger, Lu Qian, Mary W Redman, Susan S Tavernier, Lori Minasian, Ellen V Sigal, Vassiliki A Papadimitrakopoulou, Michael Leblanc, Charles S Cleeland, Samuel A Dzingle, Thomas J Summers, Herta Chao, Sheshadri Madhusudhana, Liza Villaruz, Jeffrey Crawford, Jhanelle E Gray, Karen L Kelly, David R Gandara, Lyudmila Bazhenova, Roy S Herbst, Scott N Gettinger, Carol M Moinpour
Publikováno v:
JNCI: Journal of the National Cancer Institute. 115:437-446
Background An important issue for patients with cancer treated with novel therapeutics is how they weigh the effects of treatment on survival and quality of life (QOL). We compared QOL in patients enrolled to SWOG S1400I, a substudy of the LungMAP bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1976563759de6e6c88f60ed5bcd02a8a
https://doi.org/10.1093/jnci/djad003
https://doi.org/10.1093/jnci/djad003
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-15 (2017)
Abstract The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In particular, immune modulating drugs have
Externí odkaz:
https://doaj.org/article/58a6bad9bdb6476da210f36cef7208b6
Autor:
Daniel C. Cho, Michael E. Hurwitz, Chantale Bernatchez, Yijie Liao, Ernesto Iacucci, Ahsan Rizwan, Christie Fanton, Sandra Aung, Ute Hoch, Alison L. Hannah, Jonathan Zalevsky, Mary A. Tagliaferri, Brendan D. Curti, Scott S. Tykodi, Mario Sznol, Scott N. Gettinger, Harriet M. Kluger, Cara Haymaker, Vassiliki Papadimitrakopoulou, Patrick Hwu, Salah-Eddine Bentebibel, Nizar M. Tannir, Adi Diab
This single-arm, phase I dose-escalation trial (NCT02983045) evaluated bempegaldesleukin (NKTR-214/BEMPEG), a CD122-preferential IL2 pathway agonist, plus nivolumab in 38 patients with selected immunotherapy-naïve advanced solid tumors (melanoma, re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76d9b8ad447190ee9c1740fd458386d6
https://doi.org/10.1158/2159-8290.c.6547937.v1
https://doi.org/10.1158/2159-8290.c.6547937.v1
Autor:
Katerina Politi, Monte M. Winslow, Dmitri A. Petrov, Heather A. Wakelee, Maximilian Diehn, Scott N. Gettinger, Robert Homer, Stellar Levy, Nicholas Rashleigh, Dylan G. Maghini, Laura Andrejka, Anna Wurtz, Jungmin Choi, Katherine Hastings, Deborah Ayeni, Wen-Yang Lin, Jessica A. Hellyer, Hongchen Cai, Chuan Li, Giorgia Foggetti
Supplementary Table
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19e796e9a84c5835ce2fd590b31071df
https://doi.org/10.1158/2159-8290.22540658
https://doi.org/10.1158/2159-8290.22540658
Autor:
Katerina Politi, Monte M. Winslow, Dmitri A. Petrov, Heather A. Wakelee, Maximilian Diehn, Scott N. Gettinger, Robert Homer, Stellar Levy, Nicholas Rashleigh, Dylan G. Maghini, Laura Andrejka, Anna Wurtz, Jungmin Choi, Katherine Hastings, Deborah Ayeni, Wen-Yang Lin, Jessica A. Hellyer, Hongchen Cai, Chuan Li, Giorgia Foggetti
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b566697f8331848861e25b754da8421
https://doi.org/10.1158/2159-8290.22540667.v1
https://doi.org/10.1158/2159-8290.22540667.v1